Background: The pharmacodynamic parameter that best correlates with bacteriological eradication for fluoroquinolones is the free (f) area under the 24 h serum concentration curve (AUC 24 ) to MIC (fAUC 24 /MIC) ratio. This study assessed garenoxacin fAUC 24 /MIC against ciprofloxacin-resistant Streptococcus pneumoniae using an in vitro pharmacodynamic model.
Introduction
Ciprofloxacin, the first fluoroquinolone to be used for the treatment of community-acquired respiratory infections demonstrates poor potency against Streptococcus pneumoniae, an important pathogen in community-acquired respiratory infections.
1,2 New fluoroquinolones such as gatifloxacin, gemifloxacin, levofloxacin and moxifloxacin, with significantly greater activity than ciprofloxacin against S. pneumoniae have recently been developed. [1] [2] [3] [4] The enhanced pharmacodynamic potency (relative to ciprofloxacin) of these new fluoroquinolones results from their more potent intrinsic activity against S. pneumoniae (manifested by lower MICs), as well as greater free ( f ) 5 areas under the curve (fAUC 24 ) due to higher bioavailability. [6] [7] [8] [9] These in turn result in a greater free area under the curve to MIC ratios fAUC 24 /MIC of the new fluoroquinolones for S. pneumoniae.
6-9
We have recently demonstrated that these greater fAUC 24 /MIC ratios of fluoroquinolones versus S. pneumoniae result in rapid and extensive bactericidal activity in an in vitro pharmacodynamic model with new fluoroquinolones, with no regrowth over the 48 h study period. 9 Ciprofloxacin, by comparison, demonstrated only a bacteriostatic effect against multidrugresistant (ciprofloxacin-susceptible) S. pneumoniae and regrowth occurred during therapy. 8 The growing prevalence of penicillin-resistant, macrolideresistant and recently ciprofloxacin-resistant S. pneumoniae have been reported worldwide. 3, 4, 10, 11 Although all the new fluoroquinolones rapidly eradicate penicillin-resistant and macrolide-resistant strains, it is much more difficult for new fluoroquinolones to eradicate ciprofloxacin-resistant (ParC, efflux, ParC with efflux, and ParC and GyrA) [ciprofloxacin MIC; ‡4 mg/L] S. pneumoniae. 12 The purpose of this study was to assess the activity of the new fluoroquinolone garenoxacin (currently undergoing Phase III studies) against ciprofloxacinresistant S. pneumoniae using an in vitro pharmacodynamic model.
Materials and methods

Bacterial strains and culture conditions
One wild-type fluoroquinolone-susceptible and 13 ciprofloxacinresistant S. pneumoniae obtained from an ongoing CROSS-Canadian Respiratory Organism Susceptibility Study were investigated (Table 1) . 10 The 13 ciprofloxacin-resistant S. pneumoniae included four different resistance phenotypes including, ParC mutation alone, efflux mutant alone, ParC mutant with efflux, and ParC and GyrA.
Strains were of a variety of serotypes and from different regions of Canada. 13, 14 For the pharmacodynamic studies, logarithmic phase cultures were prepared at a density equivalent to that of a 0.5 McFarland standard (1 · 10 8 cfu/mL) by suspending several colonies in cationsupplemented Mueller-Hinton broth with 2.5% lysed horse blood. This suspension was diluted 1:100 and 20 mL of the diluted suspension was further diluted in 60 mL of cation-supplemented MuellerHinton broth with 2.5% lysed horse blood (Oxoid, Nepean, Ontario). Following overnight growth at 37 C, suspensions were further diluted 1:10 and 60 mL of the diluted suspension was added to the in vitro pharmacodynamic model. Viable bacterial counts consistently yielded a starting inoculum of 1 · 10 6 cfu/mL.
9,12
Antibiotic preparations and susceptibility testing Antibiotic agents were obtained as laboratory-grade powders from their respective manufacturers (ciprofloxacin and moxifloxacin, Bayer, Mississauga, Ontario; garenoxacin and gatifloxacin, BristolMyers Squibb, Montreal, Quebec; gemifloxacin, Glaxo-SmithKline, Toronto, Ontario: levofloxacin, Janssen Ortho, Ajax, Ontario), stock solutions were prepared and dilutions were made according to the Clinical Laboratory Standards Institute-CLSI (formerly NCCLS) M7-A6 method. 15 Following two subcultures from frozen stock, antimicrobial agent MICs for the isolates were determined by the CLSIapproved broth microdilution method. 15 All MICs were performed in triplicate on separate days.
PCR amplification and DNA sequence analysis
Chromosomal DNA from each S. pneumoniae isolate was obtained by established methods and used as a template for PCR. For target gene amplification, the primers as previously described by Morrissey et al. were adapted. 13, 16 PCR conditions consisted of initial incubation at 94 C for 5 min followed by 30 cycles at 94 C for 45 s, 55 C for 30 s, and 72 C for 2.5 min and a final extension at 72 C for 7 min. Amplified gyrA and parC fragments were analysed by agarose gel electrophoresis and purified with Microcon microconcentrators (Millipore, Bedford, Massachusetts, USA) using the manufacturer's instructions. DNA retrieval was verified by gel electrophoresis and the purified products were quantified using a spectrophotometer. DNA sequencing was carried out using an ABI PRISM TM BigDye Terminator Cycle Sequencing Ready Reaction Kit (Applied Biosystems, Foster City, CA, USA). Primers used for sequencing were adapted as described by Morrissey et al. 13, 16 Sequencing conditions consisted of 25 cycles at 96 C for 10 s, 50 C for 5 s and 60 C for 4 min. Sequences were obtained using an ABI PRISM TM 310 Genetic Analyzer (Applied Biosystems) and analysed using Sequence Navigator (Applied Biosystems).
Pharmacokinetics of fluoroquinolones in the in vitro pharmacodynamic model
Experiments were performed simulating peak serum concentrations (C max ) and AUCs of garenoxacin achieved in human serum after standard oral doses (garenoxacin 400 mg once daily) ( Table 2) . 1, 17 Protein-free (unbound) serum concentrations were simulated using known protein-binding fractions (garenoxacin 75%). 1, 17 The simulated garenoxacin serum half-life was 16 h.
1,17
The pharmacokinetics of garenoxacin was evaluated by dosing 400 mg once daily in the central compartment and sampling from this compartment at 0, 1, 2, 4, 6, 12, 18, 24, 36 and 48 h. Drug concentrations in each sample were measured by disc diffusion bioassay using a susceptible strain of Bacillus subtilis. 9, 12 The linear range of the bioassay was 0.1-7 mg/L. The fAUC 24 (mg·h/L) for garenoxacin was calculated using the trapezoidal rule. 9, 12 The fAUC 24 /MIC was calculated for garenoxacin against the specific S. pneumoniae strain studied.
In vitro pharmacodynamic model/pharmacodynamic experiments
The in vitro pharmacodynamic model used in this study has been previously described. 9, 12 The bacterial inoculum at 1 · 10 6 cfu/mL was introduced into the central compartment (volume; 610 mL) of the in vitro pharmacodynamic model and exposed to garenoxacin simulating free (protein unbound) serum concentrations obtained after standard dosing. Growth controls were run in parallel with drug exposure for each experiment. Pharmacodynamic experiments were performed in cation-supplemented Mueller-Hinton broth with 2.5% lysed horse blood in ambient air at 37 C. At 0, 1, 2, 4, 6, 12, 18, 24, 36 and 48 h, samples were removed from the central compartment and viable bacteria counted by plating 100 mL of serial 10-fold dilutions onto cation-supplemented Mueller-Hinton agar with 2.5% lysed horse blood. Plates were incubated overnight at 37 C in ambient air. The lowest limit of detection was 200 cfu/mL (20 mL of an undiluted sample with 20 colonies minimum). Antibiotic carryover was prevented by adding 1% w/v MgCl 2 to the Mueller-Hinton agar supplemented with 2.5% lysed horse blood to samples before plating.
9,12
Results
The susceptibility patterns of the 14 S. pneumoniae including 1 fluoroquinolone-susceptible and 13 ciprofloxacin-resistant S. pneumoniae (ParC, efflux, ParC with efflux, and ParC and GyrA) are described in Table 1 (Table 2) . Figure 1 shows the pharmacodynamic activity of garenoxacin against selected ciprofloxacin-resistant S. pneumoniae.
The pharmacodynamic activity of garenoxacin against ciprofloxacin-resistant S. pneumoniae, simulating free serum concentrations, is displayed in Table 3 . Garenoxacin fAUC 24 /MIC 200-800 was bactericidal ( ‡3 log 10 killing) at 6, 24 and 48 h against ciprofloxacin-resistant S. pneumoniae mutants including ParC mutants only, efflux mutants only and ParC/efflux mutants (Table 3) . Garenoxacin fAUC 24 /MIC 48-96 was bactericidal ( ‡3 log 10 killing) at 24 and 48 h against ciprofloxacin-resistant S. pneumoniae mutants including ParC/efflux mutants and some ParC/GyrA mutants. Garenoxacin fAUC 24 /MIC £ 24 (all ParC and GyrA mutants) resulted in a bacteriostatic effect with regrowth at 24 and 48 h. The observed MICs of garenoxacin for S. pneumoniae studied in the in vitro model did not change during the 48 h period, even for strains where regrowth occurred. Specifically, for strains 14033, 52418, 55374 and 21181 with garenoxacin MICs of 1, 1, 2 and 2 mg/L, respectively and fAUC 24 /MIC £ 24; regrowth occurred at 24 h, yet no increase in garenoxacin MIC was observed on plates inoculated with garenoxacin 2·, 4· and 8· MIC (Table 3) . 
Discussion
As ciprofloxacin-resistant S. pneumoniae is increasing in Canada and other countries, it is important to assess the pharmacodynamic activity of new fluoroquinolones against this phenotype. 11, 18 Thus we used an in vitro pharmacodynamic model to simulate pharmacokinetic parameters (fC max and fAUC 24 ) of garenoxacin at standard oral doses used for the treatment of community-acquired respiratory infections such as pneumonia.
1,17 These 14 strains chosen for study were selected because they represented both low-level (MIC 4-8 mg/L) ciprofloxacinresistant S. pneumoniae and high-level (MIC ‡ 16 mg/L) ciprofloxacin-resistant S. pneumoniae and also demonstrated typical target site (ParC and GyrA) changes in QRDRs. 13 This study showed that when simulating garenoxacin fAUC 24 / MIC 200-800, this fluoroquinolone is bactericidal ( ‡3 log 10 killing) at 6, 24 and 48 h against ciprofloxacin-resistant S. pneumoniae mutants including ParC mutants only, efflux mutants only and ParC/efflux mutants (Table 3) . Once the garenoxacin fAUC 24 /MIC is reduced to 48-96, this fluoroquinolone is still bactericidal at 24 and 48 h (not 6 h) against ParC/efflux mutants and selected ParC/GyrA mutants. However, once the garenoxacin fAUC 24 /MIC is £24 (most ParC/GyrA mutants) this fluoroquinolone is bacteriostatic with regrowth at 24 and 48 h. This is consistent with previous reports that showed excellent eradication of S. pneumoniae with respiratory fluoroquinolones achieving an fAUC 24 /MIC of ‡30. 8, 9, 12, 19, 20 Garenoxacin has been reported to be active against ciprofloxacin-resistant S. pneumoniae including ParC and GyrA mutants. 21, 22 In S. aureus, garenoxacin has been documented both genetically and biochemically to be a dual targeting agent of both topoisomerase IV and gyrase. 23 Pharmacokinetically, garenoxacin although highly protein-bound (75%) achieves a high fAUC 24 (20 mg·h/L) resulting in a very high fAUC 24 /MIC (800) and rapid bacterial killing of ciprofloxacin-susceptible S. pneumoniae (Table 2) . 17, 24, 25 Even against ciprofloxacin-resistant S. pneumoniae with ParC mutations, garenoxacin achieves high fAUC 24 /MIC (96-400) resulting in bacterial killing (Tables 2 and 3 ). Garenoxacin pharmacodynamics in epithelial lining fluid (ELF) would also be expected to be high as the agent achieves high fAUC 24 in ELF. 26 Using an in vitro pharmacodynamic model, Lister et al. 27 reported that a garenoxacin fAUC 24 /MIC 30 was required for eradication of S. pneumoniae from the model. Using a neutropenic mouse thigh infection model, Nicolau et al. 28 reported that a garenoxacin fAUC 24 /MIC 40 versus S. pneumoniae, was required for optimization of bactericidal activity and maximal survival. It has also been reported that garenoxacin has a post-antibiotic effect of 1.4-8.2 h with S. pneumoniae. 29 Using a mouse pneumonia model, Azoulay-Dupuis et al. 30 reported that garenoxacin was highly effective in eradicating both wild-type fluoroquinolonesusceptible and fluoroquinolone-resistant S. pneumoniae with single mutations (e.g. ParC) but not fluoroquinolone-resistant S. pneumoniae harbouring double mutations (e.g. ParC and GyrA). 
Pharmacodynamics of garenoxacin versus S. pneumoniae
In summary, garenoxacin is bactericidal against ciprofloxacinsusceptible and ciprofloxacin-resistant (ParC, efflux or ParC/ efflux) S. pneumoniae when achieving fAUC 24 /MIC ‡ 48; however, garenoxacin is bacteriostatic with regrowth at 24 and 48 h against ciprofloxacin-resistant (ParC/GyrA) S. pneumoniae with fAUC 24 /MIC £ 24.
